Replies to post #208520 on Biotech Values

[mcbio]

I wouldn't worry as much about retreatment especially here with so many different programs it would seems if one is effective using alternative vectors at the minimum would give retreatment options (and I think retreatment will be a much less significant issue 5-10 years from now several different approaches seem on the horizon).

What exactly are you referring to here? I'm not aware of any approaches currently beyond what SELB is doing to potentially allow for repeat dosing/address the vector issues.

BTW on point of RGNX vectors being old, is it surprising to you then that so many companies keep inking deals with them? Wouldn't it be logical to expect better vectors to be developed over time and companies wanting access to those newer/better vectors?